grade
reagent grade
product line
Vetec™
assay
≥98%
storage temp.
2-8°C
SMILES string
NC(=O)NO
InChI
1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)
InChI key
VSNHCAURESNICA-UHFFFAOYSA-N
Gene Information
human ... RRM1(6240), RRM2(6241), RRM2B(50484)
Biochem/physiol Actions
抗肿瘤剂。通过形成自由基硝基氧灭活核糖核苷还原酶,自由基硝基氧可结合到酶活性位点的酪氨酰自由基。这可阻断脱氧核苷酸的合成,从而抑制 DNA 合成,并且诱导细胞周期同步化或 S-期细胞死亡。
Legal Information
Vetec is a trademark of Merck KGaA, Darmstadt, Germany
Still not finding the right product?
Explore all of our products under 羟基脲
signalword
Danger
hcodes
Hazard Classifications
Muta. 1B - Repr. 2
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Deepa Manwani et al.
Blood, 122(24), 3892-3898 (2013-09-21)
Recurrent and unpredictable episodes of vaso-occlusion are the hallmark of sickle cell disease. Symptomatic management and prevention of these events using the fetal hemoglobin-reactivating agent hydroxyurea are currently the mainstay of treatment. Discoveries over the past 2 decades have highlighted
Winfred C Wang et al.
Pediatrics, 132(4), 677-683 (2013-09-04)
In the BABY HUG trial, young children with sickle cell anemia randomized to receive hydroxyurea had fewer episodes of pain, hospitalization, and transfusions. With anticipated broader use of hydroxyurea in this population, we sought to estimate medical costs of care
Guido Finazzi et al.
British journal of haematology, 161(5), 688-694 (2013-04-12)
Givinostat, a histone-deacetylase inhibitor (HDACi), inhibits proliferation of cells bearing the JAK2 V617F mutation and has shown significant activity with good tolerability in patients with chronic myeloproliferative neoplasms (MPN). In this multicentre, open-label, phase II study, 44 patients with polycythaemia
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| V900323-100G | 04061833026205 |
| V900323-250G | 04061833026212 |
